ACTA News: FDA

June 27, 2014
Lynn L. Bergeson focus of Bloomberg BNA Daily Environment Report story "FDA Oversight May Be Required for New, Altered Chemicals, Products, Attorney Says."
Bloomberg BNA Daily Environment Report reported on Lynn L. Bergeson’s comments regarding final nanotechnology guidances released by the Food and Drug Administration. “The guidances reaffirm the FDA’s position that it has sufficient statutory authorities and policies to oversee the safety of products it regulates, Bergeson said. She expanded on that perspective in a memo her law firm issued. The FDA also restated its view that nanotechnology isn’t inherently safe or harmful, but that specific characteristics of individual products determine safety or harmfulness, ... read more >
March 24, 2011
Jayne Bultena Joins Bergeson & Campbell, P.C. and Brings Valuable Experience to Its FDA Practice
Bergeson & Campbell, P.C. (B&C), B&C Consortia Management, L.L.C. (BCCM), The Acta Group, L.L.C. (Acta), and The Acta Group EU, Ltd (Acta EU) are pleased to announce that Jayne Bultena has joined B&C as Of Counsel. Ms. Bultena brings a distinguished background on a wide range of matters arising under the Federal Food, Drug, and Cosmetic Act. She has represented Fortune 100 companies, start-ups, and venture capital investors on several issues, including developing and implementing life-cycle management strategies using patent and non-patent (Hatch-Waxman) options, including ... read more >
 < 1 2 View 10 | 25 | 50 | 100 per page
 
THE ACTA GROUP
Beijing, China | Brussels, Belgium | Manchester, U.K. | Washington, D.C.
Contact • Twitter
 
Privacy Policy | Terms of Use | Cookie Policy
©2022 The Acta Group All Rights Reserved.